Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Polyphenols may provide protective effect against COVID-19 disease

In the study published in the journal Integrative Physiology, the researchers found that a high intake of polyphenols may have a protective effect on patients with COVID-19 and prevent disease progression.

22 Feb 2021

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure

Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.

22 Feb 2021

Gold nanoparticles investigated as part of in vitro tool for SARS-CoV-2 drug screening

Scientists have measured the interaction of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein with nano-gold colloids. These nanoparticles functionalized with the S protein have different spectroscopic signals allowing for new information about the protein to be extracted.

21 Feb 2021

SARS-CoV-2 DNA vaccine tested in animal model

A team of experts has tested the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens.

21 Feb 2021

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

The primary aim of any vaccine is to stimulate immune functions and confer long-lasting protection. A paper recently uploaded to the preprint server bioRxiv by Tong et al. (17th Feb 2021) describes a novel vaccine utilizing PIKA adjuvant and recombinant spike proteins against COVID-19 disease that promises the generation of potent neutralization antibodies, which potentially support immune responses for years.

21 Feb 2021

Proteases modulate SARS-CoV-2 spike protein activation and deactivation

A research paper recently uploaded to the preprint server bioRxiv by Platt et al. (17th Feb 2021) aimed to identify these enzymes by computational screening and molecular docking simulations, with cathepsins B, K, L, S, and V being highlighted as probable leads.

21 Feb 2021

A different strategy for wastewater detection of SARS-CoV-2

Researchers tested a variety of RNA concentration and extraction methods and assays to develop a protocol for testing SARS-CoV-2 in wastewater, which may help improve COVID-19 surveillance.

21 Feb 2021

Cissampelos pareira L. extracts demonstrate anti-SARS-CoV-2 activity in vitro

A team of scientists from India has recently investigated the antiviral potency of a traditional medicinal plant Cissampelos pareira L. in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The findings reveal that both whole-plant extracts and bioactive compounds can inhibit SARS-CoV-2 replication by modulating estrogen receptor 1 (ESR1) activity.

21 Feb 2021

Evolution of the spike gene of SARS-CoV-2 for human adaptation

Researchers have found a 96% similarity in nucleotide sequence between bat coronavirus (RaTG13), isolated from Rhinolophus affinis bats in China in 2013, and SARS-CoV-2 and ~97% amino acid similarity with the Spike (S) protein. This S protein performs two essential roles, i.e., mediates receptor-binding and membrane fusion. Hence, spike protein is regarded as a key coronavirus determinant of host tropism.

21 Feb 2021

Study maps SARS-CoV-2 infected brains

Researchers in the United States and Canada have mapped the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the brains of people who died from coronavirus disease 2019 (COVID-19).

21 Feb 2021

Study shows real-world effectiveness of Moderna and Pfizer/BioNtech vaccines

Researchers in the United States have conducted a study demonstrating the real-world effectiveness of the recently approved Moderna and Pfizer/BioNtech vaccines at protecting against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

21 Feb 2021

Live attenuated SARS-CoV-2 vaccine candidate shows protective efficacy in vivo

A new preprint on the bioRxiv* server describes the development of a live attenuated vaccine candidate to counter the growing threat of the COVID-19 pandemic.

19 Feb 2021

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

A new study reports the development of nanoantibodies (nAbs) – also called or nanobodiesTM or single-domain antibodies – that effectively bind the SARS-CoV-2 spike protein from the ancestral Wuhan variant as well as the recently detected UK and South African variants.

19 Feb 2021

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Researchers report on a Chicken-derived antibody against SARS-CoV-2, offering preliminary data on a potential therapeutic for COVID-19 warranting further research.

19 Feb 2021

COVID-19 and lung cancer have a common pathway, say researchers

A new preprint on the bioRxiv* server describes the common features COVID-19 shares with lung cancer.

19 Feb 2021

Juvenile inflammatory rheumatic disease associated with higher antibody responses to seasonal coronaviruses

A new study released on the bioRxiv* server compared the antibodies produced in young patients with these three conditions against the two immunodominant coronavirus antigens, the spike and the nucleocapsid antigens.

19 Feb 2021

Domestic dogs unlikely to transmit SARS-CoV-2, say researchers

Researchers in Spain and Germany have conducted a study showing that domestic dogs are unlikely to contribute to the transmission and community spread of SARS-CoV-2 – the agent that causes COVID-19.

19 Feb 2021

Does climate play a large role in SARS-CoV-2 transmission?

A team of researchers from the Universidade Federal de Itajuba in Brazil has reported that weather plays a vital role in determining the transmission rate of SARS-CoV-2 infection.

19 Feb 2021

How does the SARS-CoV-2 E484K mutation increase viral fitness?

How do mutations benefit SARS-CoV-2? To explore this, a team of researchers from China took a closer look at the physical interactions that occur between the proteins after viral mutation.

19 Feb 2021

USDA, FDA highlight no credible evidence of COVID-19 transmission through food or food packaging

After more than a year since the coronavirus disease 2019 (COVID-19) outbreak was declared a global health emergency, the U.S. Department of Agriculture, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention continue to underscore that there is no credible evidence of food or food packaging associated with or as a likely source of viral transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19.

18 Feb 2021